Who
Elaine K. Sorg
Director
Company insider
Files Form 4 as: Director, Artiva Biotherapeutics; SVP, Us Commercial Operations, AbbVie.
In numbers
- Trades disclosed
- 58
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $15.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 18 Feb 2021
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 25 Apr 2023filed 27 Apr 2023 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $886K6,130 at $144.54 | filing |
| 25 Apr 2023filed 27 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $886K6,130 at $144.54 | filing |
| 25 Apr 2023filed 27 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $1.0M6,130 at $165.00 | filing |
| 17 Apr 2023filed 19 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $1.1M6,999 at $161.64 | filing |
| 17 Apr 2023filed 19 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $81K500 at $162.04 | filing |
| 3 Apr 2023filed 5 Apr 2023 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $1.4M15,002 at $93.50 | filing |
| 3 Apr 2023filed 5 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $1.4M15,002 at $93.50 | filing |
| 3 Apr 2023filed 5 Apr 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $2.4M15,002 at $160.03 | filing |
| 1 Mar 2023filed 2 Mar 2023 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $1.4M15,003 at $93.50 | filing |
| 1 Mar 2023filed 2 Mar 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $1.4M15,003 at $93.50 | filing |
| 1 Mar 2023filed 2 Mar 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $2.3M15,003 at $155.00 | filing |
| 28 Feb 2023filed 2 Mar 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code F | $3.1M19,850 at $154.28 | filing |
| 21 Feb 2023filed 21 Feb 2023 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $1.6M15,321 at $105.92 | filing |
| 21 Feb 2023filed 21 Feb 2023 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $1.6M15,321 at $105.92 | filing |
News
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseABBV · prnewswire.com · 23 Oct 2026AbbVie (NYSE:ABBV) & TScan Therapeutics (NASDAQ:TCRX) Financial ComparisonABBV · tickerreport.com · 22 Oct 2026AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian CancerABBV · cantechletter.com · 21 Oct 2026
0 headlines in the last 90 days name Elaine K. Sorg; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.